Drug Profile


Alternative Names: Cobimetinib fumarate; Cotellic; GDC-0973; RG-7421; RO 5514041; XL-518

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis; Genentech; M. D. Anderson Cancer Center; Massachusetts General Hospital; Memorial Sloan-Kettering Cancer Center; Roche; University Hospital Tubingen
  • Class Antineoplastics; Azetidines; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action Mitogen-activated protein kinase kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Breast cancer; Histiocytosis
  • Phase I/II Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 06 Oct 2017 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Second-line therapy or greater) in Spain (PO) (EudraCT2017-000830-68)
  • 06 Oct 2017 Phase-I/II clinical trials in Malignant melanoma (Monotherapy, Second-line therapy or greater) in Spain (PO) (EudraCT2017-000830-68)
  • 01 Sep 2017 Roche plans a phase III trial for Malignant melanoma (First-line therapy, Combination therapy, Late-stage disease) in Australia, Belgium, Canada, Greece, Hungary, Italy, Netherlands, New Zealand, Poland, Russia, South Korea, Spain, USA in October 2017 (NCT03273153)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top